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OBJECTIVES: Remodeling of the extracellularmatrix (ECM) is a key event in different lung disorders, such as fibrosis and
cancer. The most common cell type in the connective tissue is fibroblasts, which transdifferentiate into myofibroblasts
upon activation. All myofibroblasts express α-SMA, which has been found to be upregulated in lung fibrosis and cancer.
We evaluated the potential of α-SMA as a noninvasive biomarker of activated fibroblasts in lung fibrosis and cancer.
METHODS: Amonoclonal antibody was raised against the N-terminal of α-SMA, and a novel competitive enzyme-linked
immunosorbent assay (ELISA) measuring α-SMA was developed and technically characterized. Levels of α-SMA were
measured in the fibroblast model, “scar-in-a-jar”, and in serum from patients with idiopathic pulmonary fibrosis (IPF),
chronic obstructive lung disorder (COPD) and non–small cell lung cancer (NSCLC) belonging to two different cohorts.
RESULTS:The novelα-SMAassaywasdeveloped and validated as technically robust. Based on the scar-in-a-jar results, α-
SMAwas only present in the fibroblasts activated by TGF-β. In cohort 1, levels of α-SMAwere significantly higher in IPF,
COPD and NSCLC patients compared to healthy controls (P = 0.04, P = 0.001 and P b0.0001, respectively). The area
under the receiver operating characteristics (AUROC) for separation of healthy controls from IPF patients was 0.865,
healthy controls from COPD patients was 0.892 and healthy controls fromNSCLC patients was 0.983. In cohort 2, levels
of α-SMA were also significantly higher in NSCLC patients compared to healthy controls (P = 0) and the AUROC for
separating NSCLC and healthy controls was 0.715. CONCLUSIONS: In this study we developed and validated a robust
competitive ELISA assay targeting the N-terminal of α-SMA. The level of α-SMA was upregulated when adding TGF-β,
indicating that α-SMA is increased in activated fibroblasts. The level of α-SMA in circulation was significantly higher in
patients with IPF, COPD and NSCLC compared to healthy controls. This assay could potentially be used as a novel
noninvasive serological biomarker for lung disorders by providing a surrogate measure of activated fibroblasts.
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Extracellular matrix (ECM) remodeling is a key event in diseases such
as fibrosis and cancer [1]. Fibroblasts are the most common cell type
in connective tissues throughout the body, and the principal source of
ECM components of the tissues [2]. The major function of
fibroblasts is maintenance and synthesis of new fibrillar collagens to
maintain tissue homeostasis. However, upon activation, by either
chemical signals that promote proliferation or cellular differentiation,
fibroblasts transdifferentiate into myofibroblasts which results in an
excessive collagen deposition and tissue remodeling [1,3,4]. Conse-,
.
s
.
Table 1. α-SMA ELISA Technical Validation Data
Technical Validation Test Result
IC50 3.43 ng/ml
Detection range 0.44-25.5 ng/ml
Intra-assay variation * 8.0%
Inter-assay variation * 13.0%
Dilution recovery of human serum * 99%
Dilution recovery of human urine * 82%
Dilution recovery of rat serum * 84%
Dilution recovery of rat urine * 90%
Analyte recovery 24 h, 4°C/20°C * 102%/97%
Hemoglobin recovery * 86%
Lipemia recovery * 99%
Analyte recovery, 4 freeze/thaw cycles * 97%
Salt recovery, pH 7.0/pH 8.0 † 99%
* Percentages are reported as mean.
† Average recovery after salt interference.
Translational Oncology Vol. 12, No. 2, 2019 Serological Assessment of Activated Fibroblasts by α-SMA Holm Nielsen et al. 369quently, myofibroblasts are known to be responsible for the increased
stiffness of the ECM, as seen in fibroproliferative diseases [5]. In lung
tissue there are four possible sources of myofibroblasts; 1) resident
fibroblast proliferation and differentiation, 2) circulating fibrocytes
attracted to regions of organ injury, 3) endothelial-mesenchymal
transition and 4) epithelial-mesenchymal transition [5]. All myofi-
broblasts express α-smooth muscle actin (α-SMA), which is an actin
isoform of 42 kDa located in stem- and precursor cells [6]. α-SMA is
a well-known and characterized protein used for assessment of
activated fibroblasts in several tissues and organs including the lung
[7–10], however no serological assay is currently available. The aim of
this study was to develop and validate a competitive ELISA targeting
α-SMA and evaluate its association with lung fibroblast activity in
vitro. In addition, its potential as a noninvasive biomarker was
investigated by quantifying the concentration of α-SMA in serum
samples from patients diagnosed with different lung disorders,
including idiopathic pulmonary fibrosis (IPF), chronic obstructive
pulmonary disease (COPD) and non–small cell lung cancer
(NSCLC), in comparison to healthy controls.Methods
Reagents
All reagents used for the experiments were standard high quality
chemicals from Merck (Whitehouse Station, NJ, USA) and Sigma
Aldrich (St. Louis, MO, USA). The synthetic peptides used for
production and val idat ion were; I) Coating peptide:
Ac-EEEDSTALV-K-Bio, II) Standard peptide: Ac-EEEDSTALV,
III) Immunogenic peptide: Ac-EEEDSTALVC-KLH, and IV)
Elongated peptide (CEEEDSTALV). They were purchased from
Chinese Peptide Company, Beijing, China.
Generation of Monoclonal Antibodies
The sequence for α-SMA 3’EEEDSTALV’11 was aligned between
human, mouse, rat, chicken, bovine and rabbit (Figure 1). The first
amino acid in α-SMA is a N-acetylglutamate, hence the Ac-group in
the sequence used for this assay. Generation of monoclonal antibodies
was performed as previously described [11]. Briefly, production was
initiated by subcutaneous immunization of 4- to 5-week-old Balb/C
mice with 200 μl emulsified antigen and 50 μg immunogenic peptide
(i.e., KLH-CGG-EEEDSTALV) using Freund's incomplete adju-
vant. The immunizations were repeated every second week until
stable serum titer levels were reached. The mouse with the highest
serum titer was then rested for a month and then boosted
intravenously with 50 μg immunogenic peptide in 100 μl 0.9%
NaCl solution three days before isolation of the spleen. The spleen
cells were fused with SP2/0 myeloma cells to produce a hybridoma as
described by Gefter et al. [12] and cloned in culture dishes using theFigure 1. Alignment of the targeted α-SMA sequence in human, mous
was performed using Uniprot.semisolid medium method. The clones were plated into 96-well
microtiter plates for further growth employing the limited dilution
method to secure monoclonal growth. Supernatants were screened for
reactivity via an indirect ELISA using a streptavidin-coated plate.
AC-EEEDSTALV-K-Bio was used as screening peptide, while the
free peptide Ac-EEEDSTALV was used to further test for specificity
of clones. Supernatant was collected from the hybridoma cells and
purified using HiTrap affinity columns (GE Healthcare Life Science,
Little Chalfront, Buckinghamshire, UK) according to manufacturer's
instructions.
Ethical Statement
The production of monoclonal antibodies performed in mice was
approved by the National Authority (The Animal Experiments
Inspectorate) under approval number 2013-15-2934-00956. All
animals were treated according to the guidelines for animal welfare.
Clone Characterization
Native reactivity and peptide affinity for the standard peptide were
assessed using human serum and urine purchased from a commercial
supplier (Valley Biomedical, VA 22602, USA). Antibody specificity
was tested in a preliminary assay using deselection and elongated
peptides (i.e., standard peptide with 10 amino acid substitutions and
standard peptide with one additional amino acid at the N-terminal).
The isotype of the monoclonal antibody was determined by using the
Clonotyping System-HRP kit, cat. 5300-05 (Southern Biotech,
Birmingham, AL).
α-SMA ELISA
The α-SMA procedure was as fol lows: A 96-wel l
streptavidin-coated ELISA plate (cat. 11940279 from Roche
Diagnostics, Hvidovre, Denmark) was coated with the biotinylated
peptide (AC-EEEDSTALV-K-Bio), dissolved in assay buffer (50 mMe, rat, chicken, bovine, and rabbit species (red box). The alignment
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Figure 2. Standard curve and native reactivity. A typical standard curve and native reactivity against human serum and urine (A) and rat (B)
serum and urine diluted 1:8 for the α-SMA assay, as indicated. Signals are shown as optical density (OD) at 450 nm, subtracting the
background at 650 nm, as a function of standard peptide concentration.
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the dark with 300 rpm shaking, and subsequently washed in washing
buffer (20 mM Tris, 50 mM NaCl, pH 7.2). Thereafter, 20 μl of
peptide calibrator or sample was added to appropriate wells, followed
by 100 μl of the purified monoclonal antibody diluted in assay buffer,
and the plate was incubated for 1 hour at 20°C with 300 rpm shaking
and subsequently washed in washing buffer. One hundred microliters
of secondary horseradish peroxidase– labeled antibody
Peroxidase-AffiniPure Rabbit Anti-Mouse IgG (Cat. 315-035-045,
Jackson Immunoresearch, West Grove, PA) was diluted 1:5000 in
assay buffer and incubated for 1 hour at 20°C in the dark with 300
rpm shaking and subsequently washed in washing buffer. Finally, 100
ml tetramethylbenzinidine (Kem-En-Tec cat. 438OH) was added,
and the plate was incubated for 15 minutes at 20°C in the dark with
300 rpm shaking. In order to stop the reaction, 100 μl of stopping
solution (1% H2SO4) was added, and the plate was analyzed in the
ELISA reader at 450 nm with 650 nm as the reference (SpectraMax
M; Molecular Devices, San Jose, CA). A calibration curve was plotted
using a four-parametric mathematical fit model. Each ELISA plate
included five kit controls to monitor interassay variation. In the final
optimized ELISA, all samples were measured within the determined
measurement range of the assay, and all samples below lower limit of
measurement range (LLMR) were reported as the value of LLMR.
Technical Evaluation
All technical evaluations were performed in human serum, human
urine, rat serum, and rat urine. Quality control serum and urine
samples were used undiluted to determine linearity and calculated as a
percentage of recovery of the 100% sample. Lower limit of detectionTable 2. Patient Demographics of Cohort 1
Healthy Controls
(n = 20)
IPF
(n = 10)
Age 61.85 (1.95) 73.90 (4.79)
Male, n (%) 10 (50%) 8 (80%)
BMI 26.14 (2.67) 26.22 (1.68)
FEV1% of predicted value - 64.50 (1.51)
FEV1/FVC ratio % - 77.50 (0.85)
α-SMA (ng/ml) 7.12 11.92
Data are presented as mean (SD) unless otherwise stated. Comparison of age, gender, BMI, and α-SM
comparison of FEV1% of predicted value and FEV1/FVC ratio % was calculated using the Mann-Whi
index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.(LLOD) was calculated as the mean + 3 standard deviation (SD)
determined from 21 blank samples (i.e., buffer). Upper limit of
detection (ULOD) was determined as the mean – 3*SD of 10
measurements of the highest point on the standard curve (standard
A). The intra- and interassay variation was determined by 10
independent runs of 5 quality control samples, with each run
consisting of 2 replicas of the samples. Lower limit of measurement
range (LLMR) and upper limit of measurement range (ULMR) were
calculated based on the 10 individual standard curves from the intra-
and interassay variation. Interference was measured in healthy human
serum spiked with hemoglobin (0.08-0.50 mmol/l) or lipids
(0.04-0.56 mmol/l). The interference was calculated as the percentage
recovery of the analyte in nonspiked serum. Potential salt interference
was tested by measuring salt samples with a concentration of 8.14 g/l
NaCl at pH 7.0 and pH 8.0. The analyte stability was determined for
three healthy human serum samples incubated at either 4°C or 20°C
for 2, 4, and 24 hours. The stability of the samples was evaluated by
calculating the percentage variation from the sample kept at −20°C
(0 hour sample). Furthermore, the analyte stability was determined
for three healthy human serum samples exposed to four freeze and
thaw cycles. To assess the stability of the analyte, the percentage
recovery of the analyte was calculated from the sample that
underwent only one freeze/thaw cycle. All sample tests were run as
double determinations.
Biological Validation of α-SMA
α-SMA was measured in two different cohorts obtained from the
commercial vendor Proteogenex (Culver City, CA). Samples were
collected after informed consent and approval by the localCOPD
(n = 13)
NSCLC
(n = 9)
P Value
72.15 (3.51) 63.20 (6.70) b.001
3 (23.1%) 8 (88.9%) .005
26.12 (1.90) N/A .943
71.92 (2.96) - .0001
56.15 (3.31) - b.0001
14.23 19.45 b.0001
A levels was performed using Kruskal-Wallis adjusted for Dunn's multiple-comparisons test, while
tney unpaired t test. P values below .05 were considered significant. Abbreviations: BMI, body mass
Table 3. Patient Demographics of Cohort 2
Healthy Controls
(n = 20)
NSCLC
(n = 40)
P Value
Age 61.85 (1.95) 61.93 (2.14) .593
Male, n (%) 10 (50%) 20 (50%) 1.000
BMI 26.14 (2.67) 25.55 (4.23) .533
α-SMA (ng/ml) 7.12 10.62 .006
Data are presented asmean (SD) unless otherwise stated. Comparison of age, gender, BMI, andα-SMA
levels was performed using a Mann-Whitney t test. P values below .05 were considered significant.
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Figure 4. α-SMA in the SiaJ model. α-SMA was assessed in
supernatant of media (background, n = 18), cells w/o addition of
TGF-β (n= 18), and cells with 1 ng/ml TGF-β. Data are presented as
Tukey boxplots, and lower limit of detection of the assay is marked
with a dotted line. Significance levels: ns = no significance.
Translational Oncology Vol. 12, No. 2, 2019 Serological Assessment of Activated Fibroblasts by α-SMA Holm Nielsen et al. 371Ethics Committee and in compliance with the Helsinki Declaration
of 1975.
Cohort 1 included patients diagnosed with IPF (n = 10), COPD (n =
13), NSCLC (n = 9) and colonoscopy-negative controls (n = 20) with
no symptomatic or chronic disease. Patient demographics are shown in
Table 2. Cohort 2 included patients diagnosed with NSCLC in cancer
stage I (n = 10), II (n = 10), III (n = 10), and IV (n = 10) together with
colonoscopy-negative controls (n = 20) with no symptomatic or chronic
disease. Patient demographics of this cohort are shown in Table 3.
Scar-in-a-Jar (SiaJ) Model
Primary lung fibroblasts (Lonza, Basel, Switzerland) were cultured
in DMEM culture medium supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (P/S) at 37°C and 5%
CO2 and grown until confluency, after which the cells were lifted
from the culture flask by trypsinization and counted using a
hemocytometer. Fibroblasts were seeded into the wells of a 48-well
plate at a density of 30,000 cells/well. Twenty-four hours prior to
initiation of the experiment, the cells were serum starved and cultured
in DMEM containing 0.4% FBS and 1% P/S. All subsequent media
changes used DMEM containing 0.4% FBS and 1% P/S. For the
experimental phase, similar to Chen et al. (2009) [13], the cells were
cultured in DMEM containing 0.4% FBS, 1% P/S, 225 mg/ml Ficoll
70, 150 mg/ml Ficoll 400 (both Sigma-Aldrich, St. Louis, MO), and
1% ascorbic acid (Wako Chemicals, Neuss, Germany) for 14 days.
Media were freshly prepared and changed every 3-4 days. The cells
were stimulated with either 1 ng/ml TGF-β (R&D Systems,
Minneapolis, MN) or vehicle. To ensure cell viability at the start of
the experiment and at the termination, the AlamarBlue assay was
carried out according to manufacturer’s instructions (Thermo Fisher,Peptide Concentration (ng/mL)
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Figure 3. Assay specificity. Reactivity to the standard peptide
(Ac-EEEDSTALV), the elongated peptide (CEEEDSTALV), nonsense
peptide (PGEILGHVPG), and nonacetylated α-SMA (EEEDSTALV)
was tested for the α-SMA assay. The background signal from the
system was tested using a nonsense coating peptide (Biotin-P-
GEILGHVPG). Signals are shown as optical density (OD) at 450,
subtracting the background 650 nm, as a function of standard
peptide concentration.Hvidovre, Denmark). The supernatants were collected after each
media change and stored for biomarker assessment at −20°C.
Western Blotting
Protein concentration of the cell culture supernatant from the SiaJ
experiment was determined by Pierce BCA Protein Assay Kit (cat.
#23225, Thermo Fisher), and 10 μg protein was loaded to a 4%-12%
Bis-Tris Gel (cat. #NP0322box, Invitrogen) and separated by
SDS-PAGE. Proteins were then transferred onto a nitrocellulose
membrane. The membrane was blocked with 5% skim milk powder
in TBS-T buffer and incubated at room temperature for 1 hour. The
membranes were incubated with 1 μg/ml primary α-SMA antibody
at 4°C overnight followed by three washed with TBS-T buffer. The
membrane was then incubated in the secondary peroxidase
conjugated antibody (1:5000) followed by three times wash with
TBS-T. Finally, the results were visualized with ECL detection system
(cat. #RPN2109, Amersham Pharmacia).
Statistical Analysis
Characteristics of the cohorts are presented as a number
(frequency) and percentage for categorical variables and mean (SD)
for continuous variables. Statistical differences for categorical were
assessed using a Kruskal-Wallis test (nonparametric) for cohort 1 and
a Mann Whitney t test in cohort 2. Results are shown as Tukey
boxplots. The diagnostic power of α-SMA was investigated by the
area under the receiver operating characteristics (AUROC) curve. For
all statistical analysis performed, a P value below .05 was considered
significant. Asterisks indicate the following: *P b 0.05; **P b 0.01.
Statistical analysis and graphs were performed using GraphPad Prism
version 7 (GraphPad Software, Inc., La Jolla, CA).
Results
Selection of Peptide Target and Characterization of Antibody
Clones
The monoclonal antibody with the best native reactivity, peptide
affinity, and stability for the assay was chosen from the
antibody-producing clones generated after fusion between mouse
Figure 5. Western blot showing the specific bands of α-SMA in supernatant from the SiaJ model.Lane 1-4: Supernatant from four
replicates from the SiaJ model without addition of TGF-β. Lane 5-8: Supernatant from four replicates from the SiaJ model with addition of
1 ng/ml TGF-β. Bands were observed at 42 kDa for the supernatants with addition of 1 ng/ml TGF-β, corresponding to the molecular
weight of α-SMA.
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antibody clone NB552-2A11. Since the different proteins from the
actin family are closely related, three deselection peptides (Ac-DE-
DETTALV, Ac-EEETTALV, and K-EEEDSTALV) were included
during clone selection to ensure specificity towards the α-SMA
sequence.
Technical Evaluation
A complete technical validation was performed to evaluate the newly
developedα-SMAELISA. A summary of the technical validation can be
found in Table 1.The measurement range (LLMR to ULMR) of the
assay was determined to be 0.44-25.5 ng/ml. The intra- and
intervariation was 8.0% and 13%, respectively, based on 10
independent assays. Linearity of the human samples was observed
from undiluted to eight-fold dilution for human serum, human urine,
rat serum, and rat urine (Figure 2). Hemoglobin, lipids, and salt did not
interfere with measurements of the α-SMA analyte in serum or urine.
The stability of the analyte was acceptable both during prolonged
storage of human serum samples at 4°C and 20°C (102% and 97%,
respectively) and during four freeze/thaw cycles (97%).Co
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Figure 6. Results from cohort 1. Serum α-SMA levels were assessed
in healthy controls (n=20) and in patientswith IPF (n=10), COPD (n=
13), andNSCLC (n=9). Datawere analyzed using a Kruskal-Wallis test
adjusted for Dunn's multiple-comparisons test. Data are presented as
Tukey boxplots. Significance levels: **P b .01, ***P b .001, and ****P
b .0001.Assay Characterization
The analytes detected by the α-SMA ELISA were characterized by
testing reactivity towards synthetic peptides. The assay did not show
any reactivity towards an elongated peptide (CEEEDSTALV) or a
nonsense peptide (PGEILGHVPG) (Figure 3). No background
signal was detected against a nonsense coating peptide (Biotin-P-
GEILGHVPG), indicating specificity of the antibody. The specificity
towards the acetylated α-SMA was further characterized by
measurement of nonacetylated α-SMA (EEEDSTALV), which
showed no reactivity.
Biological and Clinical Evaluation of the α-SMA Assay
The α-SMA assay was measured in the SiaJ model and showed to
be upregulated by addition of TGF-β, indicating that α-SMA is
increased in fibroblasts activated by TGF-β (Figure 4). This was
furthermore confirmed by Western blot analysis, where α-SMA only
was detected in the supernatants where TGF-β was added (Figure 5).
Furthermore, the α-SMA assay was measured in serum from
patients with different lung disorders from two independent cohorts,
which will be described as cohort 1 and cohort 2.
Cohort 1 consisted of healthy controls and patients diagnosed with
IPF, COPD, and NSCLC. Here, patients with IPF, COPD, and
NSCLC were significantly elevated compared to healthy controls (P =
.04, P = .001, and P b .0001, respectively) (Figure 6). No significant
difference was observed between IPF patients, COPD patients, and
NSCLC patients, indicating that α-SMA may play an active role in
disease. The diagnostic power (AUROC) of α-SMA for a patient
suffering from IPF compared to healthy controls was 0.865 (95%
CI = 0.71-1.01, P = .0013, Figure 7A), COPD compared to healthy
controls was 0.892 (95% CI = 0.77-1.02, P = .0002, Figure 7B), and
NSCLC to healthy controls was 0.983 (95% CI = 0.94-1.02, P b
.0001, Figure 7C).
In cohort 2, α-SMA was measured in samples from healthy
controls and patients with NSCLC. Here, α-SMA was significantly
elevated in patients with NSCLC compared to healthy controls (P =
.006) (Figure 8A), and showed an AUROC of 0.715 (95% CI =
0.58–0.85, P = .007, Figure 8B). Thus indicating that α-SMA may
be a potential serological biomarker for lung disorders.
Discussion
In this study, we developed and characterized a competitive ELISA for
the detection of α-SMA using a monoclonal antibody detecting the
050
100
0
50
100
Healthy controls vs. IPF
Se
ns
iti
vi
ty
, %
Se
ns
iti
vi
ty
, %
Se
ns
iti
vi
ty
, %
AUC: 0.865, p=0.0013
A Healthy controls vs.COPD
AUC: 0.892, p=0.0002
B
0 50 100
Healthy controls vs.NSCLC
100% - Specificity %
0 50 100
100% - Specificity %
AUC: 0.983, p<0.0001
C
0 50 100
100% - Specificity %
0
50
100
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patients, (B) healthy controls and COPD patients and, (C) healthy controls and NSCLC patients.
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follows: 1) the development of a technical robust and specific assay
towards the α-SMA sequence Ac-EEEDSTALV; 2) α-SMA was
detectable in human and rat serum and urine; 3) α-SMA was
significantly elevated in TGF-β stimulated fibroblast (the SiaJ model);
and 4) the fragment was significantly elevated in patients with IPF,
COPD, and NSCLC compared to healthy controls. To our
knowledge, this is the first study to show that α-SMA can be
measured noninvasively in supernatant and serum with biological
relevance in patients with different lung disorders.
The α-SMA ELISA is characterized as technically robust and
accurate assay showing a dilution recovery, interference, and stability
tests within the accepted range of ±20%. The inter- and intravariation
was furthermore accepted with values of 8% and 13%, respectively,
and the measurement ranged from 0.44 to 25.5 ng/ml. The assay was
further evaluated as specific towards the acetylated N-terminal site of
α-SMA at amino acid position 3 since the first amino acid in α-SMA
consists of an N-acetylglutamate, hence the Ac-group in the sequence
used for this assay.
We hypothesized that α-SMA is a protein that is expressed on the
cell surface of fibroblasts and reflects activated fibroblasts in different
lung disorders, including fibrotic tissue. Fibroblasts are also found in
the tumor microenvironment, where the myofibroblast [or so-calledHe
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Figure 8. Results from cohort 2. (A) Serum α-SMA levels were asses
were analyzed using a Mann Whitney t test. Data are presented as Tu
was used to evaluate the ability of α-SMA to discriminate between hcancer-associated fibroblast (CAF)] has been shown to be the most
abundant stromal cell type. There are several studies supporting the
prognostic potential of quantifying α-SMA assay in relation to lung
cancer. In a study evaluating α-SMA gene expression in tumors from
263 patients with primary lung adenocarcinomas, the patients with
high α-SMA expression presented with enhanced distant metastasis
and poor prognosis [14]. Another study revealed that lung CAFs
expressed more α-SMA and had greater contractile capacity than cells
from tumor-free lung [15], similar to what is seen in lung fibrosis [9].
Moreover, when compared to normal fibroblast, lung CAFs have also
been shown to express higher levels of α-SMA and promote cellular
invasion and differentiation of the lung employed in 3D co-culture,
suggesting protumorigenic effects of α-SMA–positive CAFs [16,17].
The current prognostic potential of α-SMA has been evaluated by
histological assessment of a biopsy. The novel developed assay α-SMA
provides the possibility of a serological assessment of activated
fibroblasts and could therefore potentially be used as a noninvasive
biomarker for lung disorders.
Similar to α-SMA, another actin filament that is pathologically
relevant and that has shown to be overexpressed in lung cancer tissue
is vimentin [18]. Like α-SMA, vimentin is regarded as a canonical
marker for the epithelial-to-mesenchymal transition [19]. Similar to
the α-SMA presented here, our research group has previously shown0 50 100
0
50
100
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AUC=0.715, p=0.007
sed in healthy controls (n = 20) and NSCLC patients (n = 40). Data
key boxplots. Significance levels: **P b .01. (B) ROC curve analysis
ealthy controls and NSCLC patients in cohort 2.
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(VICM) was highly elevated in lung cancer patients compared to
healthy controls and other cancer types [20]. Clearly, this supports
the notion that intracellular proteins/actin filaments are released to
the circulation, albeit the exact underlying mechanisms require
further investigations. Still, for α-SMA, the present in vitro findings
clearly indicate that this release may be associated with TGF-β
signaling — the most prominent cytokine for induction of
fibrogenesis [21]. Interestingly, the NH2-terminal sequence of
α-SMA (Ac-EEED), which is the target of the novel α-SMA assay,
is delivered to cultured myofibroblast in the form of a fusion peptide
with a cell penetrating sequence; it inhibits their contractile activity
[22], suggesting a feedback mechanism on the contractile capacity of
activated fibroblast.
One limitation of this study includes the relatively small
population size and its cross-sectional design. Only limited data
were available from the two cohorts. Still, we were able to find the
same trend in α-SMA in both cohorts. However, whether α-SMA can
be used as a diagnostic, and maybe a prognostic biomarker, needs to
be evaluated in larger, prospective cohorts.
Conclusion
In conclusion, we have developed a specific technically robust ELISA
assay for α-SMA, which may be used for detection of activated
fibroblasts in lung disorders. Furthermore, this assay shows promise as
a novel noninvasive serological biomarker potential for lung disorders,
providing a surrogate measure of activated fibroblasts.
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